Abstract
Alveolar rhabdomyosarcoma is an aggressive skeletal muscle cancer of childhood. Our initial studies of rhabdomyosarcoma gene expression for patients enrolled in a national clinical trial suggested that platelet-derived growth factor receptor A (PDGFR-A) may be a mediator of disease progression and metastasis. Using our conditional mouse tumor models that authentically recapitulate the primary mutations and metastatic progression of alveolar rhabdomyosarcomas in humans, we found by immunoblotting and immunokinase assays that PDGFR-A and its downstream effectors, mitogen-activated protein kinase and Akt, were highly activated in both primary and metastatic tumors. Inhibition of PDGFR-A by RNA interference, small molecule inhibitor or neutralizing antibody had a dramatic effect on tumor cell growth both in vitro and in vivo, although resistance evolved in one-third of tumors. These results establish proof-of-principal for PDGFR-A as a therapeutic target in alveolar rhabdomyosarcoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Armistead PM, Salganick J, Roh JS, Steinert DM, Patel S, Munsell M et al. (2007). Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients. Cancer 110: 2293–2303.
Arndt CA, Crist WM . (1999). Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 341: 342–352.
Blandford MC, Barr FG, Lynch JC, Randall RL, Qualman SJ, Keller C . (2006). Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: a report from the Children's Oncology Group. Pediatr Blood Cancer 46: 329–338.
Capdeville R, Buchdunger E, Zimmermann J, Matter A . (2002). Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1: 493–502.
Choudhury GG, Grandaliano G, Jin DC, Katz MS, Abboud HE . (2000). Activation of PLC and PI 3 kinase by PDGF receptor alpha is not sufficient for mitogenesis and migration in mesangial cells. Kidney Int 57: 908–917.
Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. (2003). A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201–1214.
Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB et al. (2001). Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 19: 3091–3102.
Devare SG, Reddy EP, Law JD, Robbins KC, Aaronson SA . (1983). Nucleotide sequence of the simian sarcoma virus genome: demonstration that its acquired cellular sequences encode the transforming gene product p28sis. Proc Natl Acad Sci USA 80: 731–735.
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039–1043.
Epstein JA, Song B, Lakkis M, Wang C . (1998). Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor. Mol Cell Biol 18: 4118–4130.
Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H et al. (2003). Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342–4349.
Heldin CH, Westermark B . (1999). Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283–1316.
Keller C, Arenkiel BR, Coffin CM, El-Bardeesy N, DePinho RA, Capecchi MR . (2004a). Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 18: 2614–2626.
Keller C, Hansen MS, Coffin CM, Capecchi MR . (2004b). Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev 18: 2608–2613.
MacDonald TJ, Brown KM, LaFleur B, Peterson K, Lawlor C, Chen Y et al. (2001). Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 29: 143–152.
Matei D, Emerson RE, Lai YC, Baldridge LA, Rao J, Yiannoutsos C et al. (2006). Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene 25: 2060–2069.
Mehrotra M, Krane SM, Walters K, Pilbeam C . (2004). Differential regulation of platelet-derived growth factor stimulated migration and proliferation in osteoblastic cells. J Cell Biochem 93: 741–752.
Meijerink J, Mandigers C, van de Locht L, Tonnissen E, Goodsaid F, Raemaekers J . (2001). A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn 3: 55–61.
Pani L, Horal M, Loeken MR . (2002). Rescue of neural tube defects in Pax-3-deficient embryos by p53 loss of function: implications for Pax-3-dependent development and tumorigenesis. Genes Dev 16: 676–680.
Ricono JM, Arar M, Choudhury GG, Abboud HE (2002). Effect of platelet-derived growth factor isoforms in rat metanephric mesenchymal cells. Am J Physiol Renal Physiol 282: F211–F219.
Schneider L, Clement CA, Teilmann SC, Pazour GJ, Hoffmann EK, Satir P et al. (2005). PDGFRalphaalpha signaling is regulated through the primary cilium in fibroblasts. Curr Biol 15: 1861–1866.
Stover EH, Chen J, Folens C, Lee BH, Mentens N, Marynen P et al. (2006). Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci USA 103: 8078–8083.
Stover EH, Chen J, Lee BH, Cools J, McDowell E, Adelsperger J et al. (2005). The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 106: 3206–3213.
Takahashi Y, Oda Y, Kawaguchi K, Tamiya S, Yamamoto H, Suita S et al. (2004). Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. Mod Pathol 17: 660–669.
Underwood TJ, Amin J, Lillycrop KA, Blaydes JP . (2007). Dissection of the functional interaction between p53 and the embryonic proto-oncoprotein PAX3. FEBS Lett 581: 5831–5835.
Acknowledgements
We thank Dr Frederic G Barr (The University of Pennsylvania School of Medicine) for providing Pax3:Fkhr cDNA and Pax7:Fkhr cDNA, and Dr Guillermina Lozano (University of Texas M.D. Anderson Cancer Center) for providing p53 cDNA. This work was funded in part by grants from NIH RO1CA 133229, the University Research Council (UTHSCSA), the Sarcoma Foundation of America, and the Amschwand Sarcoma Cancer Foundation. Animal care costs for this study were in part defrayed by a National Cancer Institute Center grant to the San Antonio Cancer Center (Grant number P30 CA54174), of which CK is a member. We thank Dr Sharon B Murphy for critical reading of this article, and Gary Chisholm for statistical support.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Supplementary information
Rights and permissions
About this article
Cite this article
Taniguchi, E., Nishijo, K., McCleish, A. et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 27, 6550–6560 (2008). https://doi.org/10.1038/onc.2008.255
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2008.255
Keywords
This article is cited by
-
Receptor tyrosine kinase gene expression profiling of orbital rhabdomyosarcoma unveils MET as a potential biomarker and therapeutic target
Human Cell (2023)
-
Exogenous expression of the glycosyltransferase LARGE1 restores α-dystroglycan matriglycan and laminin binding in rhabdomyosarcoma
Skeletal Muscle (2019)
-
Rhabdomyosarcoma
Nature Reviews Disease Primers (2019)
-
The Tumor Microenvironment of Pediatric Sarcoma: Mesenchymal Mechanisms Regulating Cell Migration and Metastasis
Current Oncology Reports (2019)
-
Primary intracranial soft tissue sarcomas in children, adolescents, and young adults: single institution experience and review of the literature
Journal of Neuro-Oncology (2016)